1. Introduction {#sec1}
===============

Bipolar disorder (BD) is a severe and chronic mental disorder standing among the leading causes of disability worldwide ([@bib18]). BD is characterised by alternating mood states of mania and depression, interspersed with partial symptomatic recovery (euthymia). Although the precise etiopathological mechanism remains unclear, a potential role for dysfunctional immuno-inflammatory processes in BD has been postulated based on several observations, as recently reviewed ([@bib42]); some of the prominent ones being: (i) high prevalence of comorbid chronic conditions viz. cardiovascular disorders, type 2 diabetes mellitus, hypertension, obesity and autoimmune disorders ([@bib26]); (ii) signs of central nervous system (CNS) inflammation, as evidenced by increased levels of interleukin (IL)1β in the cerebrospinal fluid, and IL1β, IL1 receptor (IL1R), nuclear factor kappa B (NF-kB) subunits p50 and p65 in BD post-mortem frontal cortex with decreased levels of transforming growth factor beta 1 (TGF-β1) (an anti-inflammatory cytokine) ([@bib39]; [@bib43]; [@bib45]); (iii) inflammatory activation of the T cell/monocyte-macrophage system ([@bib2]; [@bib10]); (iv) a pro-inflammatory mRNA signature in monocytes ([@bib37]); (v) anti-inflammatory effect of antipsychotics/mood stabilisers which are the mainstay of treatment in BD ([@bib29]; [@bib37]); (vi) high rate of infectious stigma for viruses or parasites with tropism for the CNS, for example, *Toxoplasma gondii* ([@bib9]; [@bib19], [@bib20]; [@bib47]); (vii) implication of genetic factors that lead to defective immune regulation, and inefficient anti-infectious response in the modulation of BD susceptibility ([@bib7],[@bib8]; [@bib35]); (viii) elevated levels of acute-phase proteins and alterations in circulating levels of pro-inflammatory and anti-inflammatory cytokines, particularly IL6 ([@bib29]; [@bib32]).

IL6, one of the often implicated pro-inflammatory cytokines in BD at the serological level is functionally pleiotropic, released both from peripheral immune cells as well as cells of the CNS including neurons and microglia ([@bib27]). IL6 plays an essential role in the regulation of immune response, systemic inflammatory pathways, acute-phase reactions and hematopoiesis by its signalling through the human IL6 receptor (IL-6R) which exists in both membrane-bound (mIL-6R) and soluble forms (sIL-6R) ([@bib46]). It is known that signalling by IL6 can be either pro-inflammatory or anti-inflammatory based on whether the IL-6R is membrane bound or soluble -- the former being the classical anti-inflammatory signalling and the latter, pro-inflammatory trans-signalling ([@bib21]).

The *IL6* -174 G \> C (*rs*1800795) is a common single nucleotide polymorphism (SNP; minor allele frequency of 0.14; <https://www.ncbi.nlm.nih.gov/>) located in the upstream of the gene, which has been shown to influence the circulating levels of both IL6 and C-reactive protein (CRP), with G allele being the high expressor allele for *IL6* ([@bib4]; [@bib12]; [@bib40]; [@bib41]). The non-synonymous SNP of the *IL6R* gene (*rs*2228145) Asp358Ala has previously been shown to influence soluble IL-6R concentrations in an allele dependent manner ([@bib13]; [@bib15]; [@bib28]; [@bib38]; [@bib50]). IL-6 exerts its activity either by classical signalling upon binding to the membrane bound IL-6 receptor (mIL-6R) or by trans-signalling after interaction with its soluble variant (sIL-6R) issued from limited proteolytic cleavage and thereby shedding of the mIL-6R or by alternative mRNA splicing. The *IL6R rs*2228145 (A \> C; Asp358Ala) variant in the exon 9 of the *IL-6R* gene on chromosome 1q21 was demonstrated to attenuate classical IL-6 signalling and to enhance trans-signalling, as the C allele (358Ala variant) is associated with a high rate of shedding of the IL-6R leading to a two-fold increase in sIL-6R levels ([@bib16]; [@bib51]). Therefore, these functional polymorphisms could clearly influence the expression and levels of both *IL6* and *IL6R* and consequently, IL6 signalling.

Reports from different populations of the association of IL6 genetic variants and that of its receptor IL-6R with other psychiatric disorders are largely inconsistent ([@bib7],[@bib8]; [@bib23], [@bib24]; [@bib30]; [@bib44]; [@bib46]) and there is a paucity of population-based IL6 genetic data in BD with very few reports thus far, to our knowledge ([@bib6]). Moreover, studies on the relationship between immunogenetic diversity and serological levels of inflammatory markers are scarce in BD, with only two studies exploring the genetics of MBL, MASP-2 and CRP production, but with negative results ([@bib1]; [@bib14]).

The aims of the present study were: (i) to analyse the distribution of the *IL6* (-174 G \> C) *rs*1800795 and *IL6R rs*2228145 polymorphisms in French and South Indian Tamil BD cohorts and (ii) to evaluate plasma levels of IL-6 in the Indian sub-sample and their potential relationship with IL-6 and IL-6R genotypes.

2. Methods {#sec2}
==========

2.1. Study subjects {#sec2.1}
-------------------

A sample of 565 French BD patients according to DSM-IV criteria ([@bib11]), admitted into three French university-affiliated psychiatry departments (Paris-Créteil, Bordeaux and Nancy), were interviewed by trained psychiatrists, using the French version of the Diagnostic Interview for Genetic Studies (DIGS version 3.0) ([@bib34]). Psychiatric evaluations were performed to assess the severity of symptoms and level of functioning of the subjects. Severity of manic symptoms were rated by using the Young\'s Mania Rating Scale (YMRS) ([@bib52]) and depressive symptoms by Montgomery-Asberg Depression Rating Scale (MADRS) ([@bib33]). Furthermore, 201 healthy controls (HC) were recruited and interviewed with the DIGS to assess personal and family history of psychiatric disorders using the National Institute for Mental Health Family Interview for Genetic Studies (Maxwell, 1992 <https://www.nimhgenetics.org/interviews/figs/>). All patients and controls in this group were of French descent with at least three grandparents from mainland of France and were consecutively recruited between February 2006 and January 2010.

For the second sample, 152 south Indian Tamil patients who had a diagnosis of BD according to DSM-IV criteria ([@bib11]) were consecutively recruited from out-patient and in-patient services of the Department of Psychiatry at Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, a major tertiary referral centre in South India. Detailed clinical and family history, as well as history of environmental exposures were obtained for each patient through structured interviews conducted by trained psychiatrists. Psychiatric evaluations were performed to assess the severity of symptoms and level of functioning of the subjects. Severity of manic symptoms was rated using the YMRS and MADRS. Remission was defined as a score of ≤7 on YMRS, and ≤10 on MADRS. One hundred and fifty-nine HC were also enrolled who were matched with respect to age, sex and ethnicity, and were without a personal or a first degree family history of psychiatric, neurological or autoimmune disorders. All subjects in this group were of south Indian Tamil ethnicity.

While genotype analyses were carried out in both the French and south Indian Tamil samples, IL6 levels in plasma were measured only in the latter group, which remained on medication during enrolment into the study. Among them, 88% were on mood stabilizers (either of lithium, valproate, or carbamazepine). About 82% of the patients were treated with antipsychotic medication at least once during their lifetime, including typical (22.7%), atypical (43.7%), and a combination of both (33.6%) antipsychotics. Also, 9% of the patients were treated with antidepressants, 56% with anxiolytics, and 9% of the patients had at least once undergone electroconvulsive therapy.

In both samples, age at onset (AAO) was defined as the age at which the first mood episode (depressive, manic or hypomanic) occurred. The threshold for early-onset BD (AAO before the age of 22 years) was defined on the basis of previous admixture analyses in eight independent samples ([@bib17]).

The power of the study, analysed using the Genetic Association Study (GAS) Power Calculator that is used to compute statistical power for one-stage genetic association studies, was found to be \>70% assuming the genotype relative risk at 1.5 and the significance level set to 0.05.

In both the Indian and the French sample, all participants provided written informed consent for participation in the study, which had previously been reviewed and approved by the respective institutional ethics committees.

2.2. *IL6* and *IL6R* genotyping {#sec2.2}
--------------------------------

Genomic DNA was extracted from peripheral blood leukocytes ([@bib31]). Polymorphisms in the upstream promoter region of the *IL6* gene -174 G \> C (*rs*1800795) and in the coding region of *IL6R* gene (*rs*2228145) Asp358Ala were analysed by allelic discrimination method (Step One Plus™ Real Time PCR System, Applied Biosystems, FosterCity, CA, USA) with TaqMan 5′ Nuclease Assays using allele specific fluorogenic oligonucleotide probes -- C\_\_1839697_20 and C\_\_16170664_10 respectively, following manufacturer\'s instructions.

2.3. Plasma measurement {#sec2.3}
-----------------------

The plasma levels of IL6 were assessed using the "Human IL-6 ELISA Kit" (Diaclone, Besançon, France) following manufacturer instructions.

2.4. Statistical analysis {#sec2.4}
-------------------------

Categorical variables were expressed as frequencies and percentages, and continuous variables were expressed in terms of median values for each group. The distribution of allele and genotype frequencies was compared between BD cases and healthy controls using chi-square test with Bonferroni correction. The odds ratio (OR) with 95% confidence interval was determined for each allele and genotype. Shapiro-Wilk\'s test was performed to check for normal distribution of the data. The differences in plasma IL-6 levels between cases and controls were analysed using two-tailed Mann-Whitney U test and Kruskal-Wallis test. A corrected *p*-value (two tailed) \<0.05 was considered significant. IBM SPSS v16 software was used for performing linear regression analyses with age, gender, BMI, smoking status, symptom severity as covariates. Winpepi COMPARE 2 v3.85 software was used to test for genotypic associations, and GraphPad Prism 6 was used to compare plasma IL6 levels between cases and controls.

3. Results {#sec3}
==========

Demographic characteristics of the study subjects are as shown in [Table 1](#tbl1){ref-type="table"}.Table 1Demographic & clinical characteristics.Table 1French subjectsSouth Indian Tamil subjectsBD (*n* = 565)HC (*n* = 201)BD (*n* = 152)HC (*n* = 159)**Age at inclusion (years)**Mean ± SD42.5 ± 12.942.2 ± 11.932.49 ± 10.6333.79 ± 11.02Median (Range)42 (18--80)44 (19--64)31 (18--60)30 (18--63)**Gender**Male, n (%)235 (41.6)119 (59.2)75 (49.4)88 (55.3)**Age at onset (years)**[a](#tbl1fna){ref-type="table-fn"}Mean ± SD24.9 ± 9.923.83 ± 6.99Median (Range)22 (6--67)22 (13--51)**Plasma IL-6 Levels (pg/mL)**[a](#tbl1fna){ref-type="table-fn"}Median6.385.05Interquartile range3.5--9.13.1--8.0Mean ± SD7.6 ± 9.36.1 ± 5.2**Symptom severityYMRS**Acute phase18.1 ± 10.3Residual/remission phase1.9 ± 2.5**MADRS**Acute phase12.3 ± 12.2Residual/remission phase2.2 ± 6.0[^1][^2]

Two polymorphisms -- one in the promoter region of the *IL6* gene (*rs*1800795) and one in the *IL6R* gene (*rs*2228145) -- were characterized in BD patients and HC from two different populations -- French, and south Indian Tamil. The genotype and allelic frequencies shown in Tables [2](#tbl2){ref-type="table"}, [3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"} were found to be in Hardy Weinberg equilibrium in both cases and controls except for the polymorphism *IL6R rs*2228145 in the French BD group.Table 2Frequency distribution *IL6 rs*1800795 and *IL6R rs*2228145 genotypes.Table 2*IL6 rs*1800795French sampleSouth Indian Tamil sampleBD\
n = 565%HC\
n = 201%POR95% CIBD\
n = 152%HC\
n = 159%PPcOR95% CI**Genotype**CC21337.97136.40.7163.985.00.64GC25345.09347.70.524227.64226.40.80GG9617.13115.90.7010468.410968.60.98**Allele**C67960.423560.3-5417.85818.2-G44539.615539.70.9625082.226081.80.87***IL6R**rs*2228145Genotype**AA20336.26734.50.688757.28251.60.31CA24643.89951.00.085032.97044.00.040.120.620.38--1.01CC11220.02814.40.09159.974.40.060.182.360.87--7.04Dominant model**Allele**A65258.123360.1-22473.723473.6-C47041.915539.90.418026.38426.40.97[^3]Table 3Frequency distribution *IL6 rs*1800795 genotypes in early- and late-onset bipolar disorder.Table 3*IL6 rs*1800795EOBD\
n = 232%LOBD\
n = 333French sampleOR^2^ 95% CIOR^3^ 95% CI%HC\
n = 201%P^1^P^2^P^3^OR^1^ 95% CI**Genotype**CC9039.312336.97136.40.570.540.90GC9943.215446.29347.70.480.360.75GG4017.55616.83115.90.840.670.78**Allele**C27960.940060.123560.3\-\--G17939.126639.915539.70.770.840.95**South Indian Tamil sampleEOBD**%**LOBD**%**HC%P**^1^**P**^2^**P**^3^**OR**^1^**95% CIOR**^2^**95% CIOR**^3^**95% CIn = 55n = 67n = 159Genotype**CC11.857.585.00.150.310.47GC1527.31928.34226.40.890.900.76GG3970.94364.210968.60.430.740.52**Allele**C1715.52921.65818.2\-\--G9384.510578.426081.80.210.500.40[^4][^5][^6]Table 4Frequency distribution of *IL6R rs*2228145 genotypes in early- and late-onset bipolar disorder.Table 4*IL6R rs*2228145EOBD\
n = 232%LOBD\
n = 333French sampleOR^2^ 95% CIOR^3^ 95% CI%HC\
n = 201%P^1^P^2^P^3^OR^1^ 95% CI**Genotype**AA7432.212939.06734.50.100.610.31CA9842.614844.79951.00.620.080.16CC5825.25416.32814.40.010.0060.571.73 (1.14--2.63)2.00 (1.22--3.32)**Allele**A24653.540661.323360.1\-\--C21446.525638.715539.90.0080.050.971.38 (1.08--1.76)1.31 (0.99--1.72)South Indian Tamil sample**EOBD**%**LOBD**%**HC%P**^1^**P**^2^**P**^3^**OR**^1^**95% CIOR**^2^**95% CIOR**^3^**95% CIn = 55n = 67n = 159Genotype**AA3360.03653.78251.60.490.280.76CA1629.12537.37044.00.340.050.350.52 (0.25--1.05)CC610.969.074.40.720.080.182.66 (0.70--9.69)**Allele**A8274.59772.423473.6\-\--C2825.53727.68426.40.700.840.79[^7][^8][^9]

We found that allele and genotype frequencies did not differ significantly between cases and controls for both polymorphisms in the French population. In the Indian sample, comparison of the *IL-6* and *IL-6R* allele and genotype distribution showed that the frequency of the *IL-6R rs*2228145 CA genotype was higher in HC than in patients (P = 0.04, Pc = 0.12), while that of the *IL-6R* CC genotype was higher in cases as compared to HC (P = 0.06, Pc = 0.18), albeit failing to reach statistical significance after correction for multiple comparisons ([Table 2](#tbl2){ref-type="table"}). The same trend was observed in the French sample. The *IL6R rs*2228145 heterozygous CA genotype was more frequent in controls (P = 0.08, Pc = 0.24), and the CC genotype was more frequent in cases (P = 0.09, Pc = 0.27), although the differences were not statistically significant. Altogether, these observations suggest a possible recessive susceptibility status of the *IL6R rs*2228145 C allele.

Upon stratifying both populations based on the age at onset as early onset BD (EOBD) and late onset BD (LOBD), in the French population, we found no associations with the *IL6 rs*1800795 variant. The *IL6R rs*2228145 C allele and CC genotype frequencies were significantly higher in EOBD as compared to LOBD (P = 0.01, Pc = 0.03, OR = 1.73, 95% CI = 1.14--2.63) and to HC (P = 0.006, Pc = 0.018, OR = 2.36, 95% CI = 0.87--7.04). A similar trend, although statistically non-significant, was observed in the Indian sample with respect to *IL6R rs*2228145 CC genotype on comparing EOBD to controls (P = 0.05, Pc = 0.15, OR = 1.52, 95% CI = 0.25--1.05); however, the difference was not replicated at the allelic level, or when comparing EOBD with LOBD ([Table 3](#tbl3){ref-type="table"}).

In the South Indian population, we found that plasma IL-6 levels were significantly higher in BD as compared to HC (median: 6.38 pg/mL *vs* 5.05 pg/mL, P = 0.007 in patients and HC respectively) ([Fig. 1](#fig1){ref-type="fig"}). Comparison of plasma IL-6 levels between BD cases in acute phase and those in remission/residual phase of the disease, or with controls did not show any significant differences ([Fig. 2](#fig2){ref-type="fig"}). However, when the levels of subjects enrolled at remission/residual phase were compared with healthy controls, we observed that the IL-6 levels were significantly higher in patients than in the controls (median: 7.68 pg/ml *vs* 5.23 pg/ml, P = 0.005 in patients and HC respectively). The plasma IL-6 levels were not influenced by the *IL-6* and *IL-6R* alleles/genotypes both in BD and in controls (data not shown). Linear regression analyses showed that IL-6 levels were not influenced by age, gender, BMI, smoking status, or severity of symptoms as assessed by the MADRS or the YMRS clinical assessments.Fig. 1Median plasma IL-6 levels between BD cases and controls.Fig. 1Fig. 2Median plasma IL-6 levels between BD cases in Acute phase \[BD(A)\], Residual Phase/Remission \[BD(R)\] and controls (SNC).Fig. 2

4. Discussion {#sec4}
=============

Converging evidences point towards the involvement of inflammatory mechanisms, at least in a subset of patients, in BD. Overall, BD could be viewed as a multi-system inflammatory disease, owing to the high burden of comorbid disorders associated with inflammation and immune abnormalities ([@bib26]). As a marker of such dysimmunity, IL6 was amply studied and implicated in the risk to develop BD.

In the present study, we observed that the French and the south Indian Tamil cohorts differ in terms of allelic frequencies for both *IL6* rs1800795 and the *IL6R* rs2228145 polymorphisms. The minor G allele of the IL6 rs1800795 variant was found almost three times more frequent in the French sample (60%) as compared to the south Indian Tamil sample (18%). However the frequencies were comparable to that of 1000 Genomes reference data ([@bib48]) for European (35--51%) and South Asian ancestries (11--17%) respectively. Similarly, for the IL6R rs2228145 polymorphism, the frequency of the minor C allele was comparable to the reference data of European ancestry (25--41%) for our French sample (40%), and with the South Asian ancestry (27--31%) for our south Indian Tamil sample (26%), although widely different between the two studied samples.

Then, we found that the *IL6R rs*2228145 C allele and CC genotype were associated with EOBD in a relatively large French sample, with similar trend being observed in the Indian population-group. Functionally, the *IL6R rs*2228145 attenuates classical IL-6 signalling and to enhances trans-signalling, as the C allele (358Ala variant) is associated with a high rate of shedding of the IL-6R leading to a two-fold increase in sIL-6R levels ([@bib16]; [@bib51]). Indeed, trans- and not classical IL-6 signalling and thus IL6-related pro-inflammatory processes have been found to be associated with chronic immune/inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease ([@bib16]). This could partly explain the herein observed association between the *IL6R* C allele at homozygous state early-onset BD, which is considered as the more severe form ([@bib36]).

The difference in IL-6 signalling was also reflected by the higher levels of circulating IL-6 observed in the Indian BD patients who were in residual phase or remission, in agreement with earlier reports ([@bib22]; [@bib25]; [@bib49]). However, we did not find any significant difference on comparing patients in acute phase with those in residual/remission phase or with controls. Also, no phasic differences in IL-6 levels within the disease groups were observed, and the alterations in the plasma IL-6 levels were independent of the studied *IL-6* and *IL-6R* genetic variants.

An earlier meta-analysis of 30 studies on cytokine alterations in BD found that concentrations of IL-6 and sIL-6R were significantly elevated in BD patients compared to healthy controls ([@bib32]). One study examined the phasic differences of cytokine levels in BD and found that IL-6 was elevated in acute mania and in acute depressive phases compared to healthy subjects ([@bib3]). A finding of T-cell immune activation and increased B- cell numbers -- markers of immune dysregulation in BD in an earlier study, was attributed to the stimulatory effect of IL-1 and IL-6 cytokines which were also found to be raised in this condition ([@bib2]). Hamdani *et al* found a correlation of IL-6 mRNA expression levels and cognitive deterioration index in BD patients infected with *Toxoplasma* gondii. Taking IL-6 as a marker of long-term exposure to inflammation, it has been proposed that *IL-6* expression could help design personalized treatment for BD by acting as a predictor of cognitive deterioration ([@bib20]).

Based on data from twin families (n = 2360), van Dongen *et al* observed that the functional *IL-6R* SNP *rs*2228145 contributed 51% to the heritability of the sIL-6R which was estimated at 72% ([@bib50]). Cetin *et al* reported that the sIL-6R levels were increased in BD patients with and without subsyndromal symptoms as compared to healthy control subjects. However, they did not find any differences between the two BD subgroups ([@bib5]).

There is paucity of comprehensive population based data on the *IL6* and *IL6R* genetic variant distribution and concerning their potential relationship with IL-6 expression in BD. Here, we addressed, for the first time to our knowledge, these aspects in two genetically distant population-groups -- French and south Indian Tamil. In particular, being an understudied ethnicity compared to European and other populations, inclusion of genetic data from the south Indian Tamil population in a reasonable large sample adds to the novelty of our study. Despite the importance of the trans-ethnic aspect of the study, a limitation is the non-availability of IL-6 plasma level data of the French sample. Also in the south Indian Tamil cohort, all patients remained on medication during this study. This could be a potential limitation with respect to the IL-6 quantitation given that pro-inflammatory cytokines might be modified by the administration of psychoactive drugs ([@bib32]).

Nevertheless, the present study uncovers the possible association of the IL-6R genetic diversity with BD and replicates that of increased IL6 plasma levels. These trans-ethnic findings warrant further investigation and replication in larger cohorts.
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[^1]: BD: bipolar disorder; HC: healthy controls; SD: standard deviation; pg/mL: picograms per milliliter.

[^2]: Data not available for all subjects (Age at onset data missing for 35 BD subjects in the French sample and 30 in the Indian sample; IL-6 levels: not measured in the French sample and data missing for 2BD and 6 HC subjects in the Indian sample).

[^3]: Missing genotypes represent less than 5% of the sample. BD: bipolar disorder; HC: healthy controls; P: *p*-value; Pc: corrected *p*-value; OR: odds ratio; CI: confidence interval.

[^4]: EOBD: early onset bipolar disorder; LOBD: late onset bipolar disorder; HC: healthy controls; P: *p*-value; Pc: corrected *p*-value; OR: odds ratio; CI: confidence interval.

[^5]: P^1^, P^2^ and P^3^ corrected *p*-values correspond to EOBD vs LOBD, EOBD vs controls and LOBD vs controls comparisons, respectively.

[^6]: OR^1^, OR^2^ and OR^3^ odds ratios correspond to EOBD vs LOBD, EOBD vs controls and LOBD vs controls comparisons, respectively.

[^7]: EOBD: early onset bipolar disorder; LOBD: late onset bipolar disorder; HC: healthy controls; P: *p*-value; Pc: corrected *p*-value; OR: odds ratio; CI: confidence interval.

[^8]: P^1^, P^2^ and P^3^ corrected *p*-values correspond to EOBD vs LOBD, EOBD vs controls and LOBD vs controls comparisons, respectively.

[^9]: OR^1^, OR^2^ and OR^3^ odds ratios correspond to EOBD vs LOBD, EOBD vs controls and LOBD vs controls comparisons, respectively.
